EGFR polysomy in squamous cell carcinoma of the thyroid. Report of two cases and review of the literature

Luca Reggiani Bonetti, Massimo Lupi, Margherita Trani, Nicoletta Trani, Giuliana Sartori, Laura Schirosi, Stefania Bettelli, Giuliana Zanelli, Livia Maccio, Antonio Maiorana

Research output: Contribution to journalArticlepeer-review


Aims and background. Primary squamous cell carcinoma of the thyroid gland (PSCCT) is an uncommon malignancy characterized by a poor prognosis. A radical surgical approach combined with radiotherapy or chemotherapy is the generally accepted treatment for this tumor. The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor modulating the cell proliferation and biological progression of many human epithelial tumors. The EGFR overexpression in PSCCT suggests an additional therapeutic option for the treatment of this tumor. Methods and study design. The clinicopathological features and immunohistochemical profiles of two cases of primary squamous cell carcinoma of the thyroid in a 66-year-old and an 83-year-old woman are presented. EGFR status was valued in both cases. Results. Overexpression of EGFR protein was detected in 50% and 75% of the tumor cell membranes. EGRF gene polysomy was detected in both tumors. Conclusions. Pharmaceuticals targeting EGFR may help to provide the rationale for an additional, novel therapeutic option for this rare tumor, especially when other therapeutic options have been exhausted.

Original languageEnglish
Pages (from-to)503-507
Number of pages5
Issue number3
Publication statusPublished - May 2010


  • EGFR
  • Polysomy
  • Squamous cell carcinoma
  • Thyroid

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'EGFR polysomy in squamous cell carcinoma of the thyroid. Report of two cases and review of the literature'. Together they form a unique fingerprint.

Cite this